ABSTRACT. We prepared monospecific antiserum in rabbits against medium chain acyl-CoA dehydrogenase (MCAD) purified from rat liver and studied the biosynthesis of MCAD in cultured skin fibroblasts from patients with MCAD deficiency using the antibody. Cells were incubated with ~5S]methionine. The labeled MCAD was immunoprecipitated using the anti-rat MCAD antiserum and Staphylococcus aureus cells and then analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. We first demonstrated that antirat MCAD antibody crossreacted specifically with human MCAD. In 13 MCADdeficient cell lines tested, the residual MCAD activity ranged from 5 1 2 % of the mean of normal controls, but the variant MCAD in all of these cells was indistinguishable from the normal human MCAD on the basis of molecular size, indicating that MCAD deficiency in all of these patients is most likely due to point mutation ( Triton X-100, and 0.25% SDS PAGE, polyacrylamide gel electrophoresis PBS, phosphate-buffered saline SCAD, short chain acyl-CoA dehydrogenase SDS, sodium dodecyl sulfate MCAD deficiency is an inborn error of fatty acid metabolism. MCAD deficiency is clinically identified by fasting intolerance,
recurrent episodes of hypoglycemic coma accompanied by medium chain dicarboxylic aciduria, a failure of ketogenesis, and low plasma and tissue carnitine levels. Since it was first characterized in 1982 (1) (2) (3) , at least 30 patients with this disease have been confirmed (4, 5) (Hale D, and Coates P, unpublished observations). In some patients, this disease may be severe and fatal. For the most part, however, their epidoses of illness are relatively mild and can be prevented by avoiding prolonged fasting. Biochemically, MCAD deficiency has been demonstrated in liver (2), cultured fibroblasts (1, (3) (4) (5) , and leukocytes (4) . However, the molecular aspects of the mutation of the enzyme have not been studied.
MCAD (6) is one of the three acyl-CoA dehydrogenases which catalyze the first reaction step of the @-oxidation cycles in the catabolism of fatty acids. The two others are SCAD and LCAD (7, 8) . In addition, two other acyl-CoA dehydrogenases which catalyze dehydrogenation of branched chain acyl-CoAs in the metabolism of the branched chain amino acids are known (9, 10) . We have recently purified MCAD and the four other acylCoA dehydrogenases to homogeneity from rat liver mitochondria, and extensively characterized their physical and biochemical properties ( 1 1 -1 3) .
All acyl-CoA dehydrogenases share many molecular features (10-13) and catalytic mechanisms (14) (15) (16) . These enzymes catalyze the removal of one hydrogen each from the a-and @-positions of appropriate acyl-CoA substrates via the formation of a charge transfer complex ( 14-16). They require ETF ( 17) as electron acceptor. In mitochondria, electrons are further transferred to the main mitochondrial electron transport chain via ETF-dehydrogenase and coenzyme Q (18) . Each dehydrogenase is a tetramer of identical subunits with a subunit molecular weight ranging from 4 1 to 45 kDa. The subunit molecular weight of rat MCAD is 45 kDa. Each subunit contains 1 mol of FAD. We raised antisera in rabbits against the individual rat acyl-CoA dehydrogenases. Each antiserum was monospecific to the corresponding enzyme but did not cross-react with any of the other acyl-CoA dehydrogenases (1 1-13 ). In addition, using a cell-free translation system consisting of rabbit reticulocyte lysate directed by rat polysomal RNA and immunoprecipitation, we have shown that like other mitochondrial matrix enzymes encoded by nuclear genes, rat acyl-CoA dehydrogenases are each synthesized in the cytosol as a precursor, 2-4 kDa larger than the corresponding mature enzymes. The rat precursor MCAD is 49 kDa, 4 kDa larger than the mature rat MCAD (19) . The precursors of MCAD and other acyl-CoA dehydrogenases are then imported into mitochondria by an energy dependent mechanism and finally processed to the mature form by cleaving their extended sequence (19) . The synthesis of precursor and mature MCAD has been demonstrated in cultured Buffalo rat liver cells in situ by labeling the cells with [35S]methionine in the presence or absence of an inhibitor of mitochondria1 energy metabolism such as DNP or rhodamine 6G, and detecting the product using immunoprecipitation and SDS-PAGE (19) .
Recently, we have shown that the antirat MCAD antibody specifically cross-reacts with human MCAD and that normal human MCAD is 1 kDa larger than rat MCAD, as measured by the mobility on SDS-PAGE (Ikeda Y, Tanaka K, unpublished observations). By contrast, the sizes of other human acyl-CoA dehydrogenases were the same as those of their rat counterparts. Herein, we report the biosynthesis of normal and variant MCAD in cultured human fibroblasts using [3SS]methionine labeling, immunoprecipitation, and SDS-PAGE analysis. Preparation of antibody against MCAD. MCAD was purified to homogeneity from rat liver mitochondria as described in our previous reports (1 1). Antiserum against rat MCAD was raised in a rabbit and partially purified by twice fractionating with 50% saturation of ammonium sulfate as previously described (1 1). The antibody was monospecific to rat (1 1) and human MCAD. It was capable of precipitating approximately 15 pg of the rat MCAD per 100 p1 antiserum. Labeling offibroblasts in culture. Fibroblasts were grown in Eagle's minimum essential medium supplemented with 10% fetal calf serum, nonessential amino acids, and kanamycin (growing medium). They were maintained at 37" C in a 5% CO, atmosphere. The confluent monolayers of fibroblasts in 6-cm dishes (approximately 5 x lo6 cells/dish) were labeled with [35S] methionine (50-100 &i) in 5 ml of "labeling media" containing 60% Puck's saline F, 15% dialyzed fetal calf serum, and 10% glucose as previously described (22) . The dishes were incubated at 37" C for 1 h. After removing the labeling medium, cells were washed with PBS and harvested by adding 1 ml of a buffer containing 150 mM NaCl, 10 mM EDTA, pH 7.4, 0.5% Triton X-100, 0.25% SDS, and 2% unlabeled methionine (NETS/ methionine) to each dish. The solubilized cell extract was subjected to immunoprecipitation. When rhodamine 6G was used, it was added to the medium at a final concentration of 2.1 pM, 30 min before the medium was replaced with the labeling medium containing [35S]methionine. The dish was then incubated at 37" C for 60 min in the labeling medium containing the same concentration of rhodamine 6G. The labeling and extraction of cells were performed as described above.
MATERIALS AND METHODS

Materials
Immunoprecipitation and SDS-PAGE. One ml of sample prep- VARIANT MEDIUM CHAIN ACYL-COA DEHYDROGENASE 845 aration solubilized in NETSImethionine-buffer was centrifuged for 30 min at 105,000 x g. The supernatant was incubated at 25" C for 30 min with 100 pl of S. aureus cell suspension (10% w/v) to remove proteins which bind to S. aureus cells. After centrifugation, the resulting supernatant was mixed with 10 p1 of antirat MCAD antibody, and the mixture was allowed to stand at 4" C for 12 h. The immune complexes were then recovered by adding 10 volumes of S, aureus cell suspension per volume of antibody, followed by centrifugation. Subsequent washes of the immunoprecipitates were performed as described (22) . Slab SDS-PAGE was performed using 9% gels (0.8 mm thick) according to the method of Laemmli (23) . Gels were stained with Coomassie brilliant blue, treated with Autofluor (National Diagnostics), then dried and fluorographed according to the supplier's directions. X-ray film (XAR-5, Kodak) was used to visualize the labeled protein bands in the fluorographed gels. The following I4C-labeled proteins were used as molecular weight markers: phosphorylase b (94 kDa), bovine serum albumin (68 kDa), ovalbumin (46 kDa), and a-chymotrypsinogen (26 kDa).
Assay of acyl-CoA dehydrogenases. The assays were performed as previously described (4), essentially according to the method of Frerman and Goodman (24) . This method determines acylCoA dehydrogenase activity by measuring the rate of decrease of fluorescence of oxidized ETF at 496 nm, as ETF becomes reduced by the acyl-CoA dehydrogenase-catalyzed electron transfer. Enzyme activity was expressed as nmol ETF reduced per min per mg protein. Protein concentration was determined by the method of Lowry et al. (25) .
RESULTS
Activity of acyl-CoA dehydrogenases.
Activities of short, medium and long chain acyl-CoA dehydrogenases in 13 MCADdeficient cell lines and three LCAD-deficient cell lines are listed in Table 1 . The MCAD activities in MCAD-deficient cells ranged from 5.4 to 12.1% of the mean of 43 normal controls while LCAD activities were within a range of 2 SDs from the mean of controls in most of these cells. SCAD activities in these cells were
MCAD deficient
lower than normal, ranging from 37 to 62% of the mean of 39 controls. By contrast, MCAD and SCAD activities were within normal limits in three LCAD-deficient cell lines while LCAD activities were only 8.0 to 9.4% of the mean of normal controls.
Biosynthesis of MCAD in normal human fibroblasts. First, cultured normal human fibroblasts were incubated with [35S] methionine in the absence of mitochondria1 inhibitor. The labeled products were immunoprecipitated using antirat MCAD antibody and S. aureus cells and then analyzed by SDS-PAGE. A sharp labeled band with a molecular weight of 46 kDa was observed as shown in Figure 1 , lane 1. We have shown previously that the molecular size of MCAD immunoprecipitated from human liver was 46 kDa, 1 kDa larger than the size of rat MCAD. The labeled band was not detected in the competition experiment in which an excess of the purified rat MCAD was added prior to the addition of the antibody to compete with a small amount of labeled MCAD for anti-MCAD antibody (lane 2), confirming the identity of the labeled band as MCAD.
Biosynthesis of medium chain acyl-CoA dehydrogenase in the mutant cells. The synthesis of MCAD in the absence of rhodamine 6G was studied in 11 MCAD-deficient cell lines and three LCAD cell lines using the same method. As shown in Figure 2 , mutant MCAD were actively synthesized in all 11 MCADdeficient cell lines. The molecular size of the mutant MCAD was identical to the normal MCAD detected in a normal cell line and three LCAD-deficient cell lines.
We then labeled a normal and 12 MCAD-deficient cell lines with [35S]methionine in the presence and absence of rhodamine 6G. A radioactive band of precursor MCAD (molecular weight 50 kDa), which was 4 kDa larger than the mature MCAD, was detected in the normal cell line (Fig. 3) . Also, in each of the 12 MCAD-deficient cell lines, an intensely labeled radioactive band, each 4 kDa larger than the corresponding mature variant MCAD, was detected (Fig. 3) . The molecular sizes of the precursor MCAD in mutant cells were all identical to that detected in normal cells. No heterogeneity was observed among the 12 mutant cell lines studied. 
LCAD
DISCUSSION
is the same as that of normal MCAD, it is likely that this variant allele is due to a point mutation, producing a c~alytically incomWe have in this study that human MCAD is petent enzyme. However, there is still a possibility that there are synthesized as a precursor (50 kDa), 4 kDa larger than the mature multiple variant alleles, each due to a point mutation which MCAD (46 kDa). We showed previously that the precursor of occurs at a different position in the gene. rat MCAD (49 kDa) was also 4 kDa larger than its mature counterpart (45 kDa). Furthermore, the size difference between the precursor and the mature enzyme was identical in human and rat for IVD (2 kDa) (22) and for the a-subunit of ETF (3 kDa) (26) . These observations suggest that the extended sequences in the precursor enzymes in humans are similar or identical to those in their rat counterparts.
We examined the synthesis of mutant MCAD in 13 MCADdeficient cell lines. MCAD was actively synthesized in all of these cell lines. The molecular sizes of both precursor and mature forms of MCAD's were identical to those of normal MCAD as determined on SDS-PAGE. There were no recognizable differences in the intensity of labeling and molecular size of MCAD among the 13 MCAD-deficient cell lines studied. This is in contrast to our recent findings on isovaleric acidemia and glutaric aciduria type I1 cells. We have shown that there are five distinct variant alleles among the 15 isovaleric acidemia cell lines tested. These variant alleles were distinguished based on the ability of the cells to synthesize IVD and on the molecular size of variant that is immuno-cross-reactive to antiserum raised against the rat enzyme (22) . Similarly, three distinct variant alleles were detected among three glutaric aciduria type I1 cell lines due to ETF deficiency based on the ability of the cells to synthesize the ETF a-subunit and on the molecular size of the ETF a-subunit that is immuno-cross-reactive to antibody against the rat ETF asubunit (26) . The lack of heterogeneity in the 13 MCAD-deficient cell lines in their ability to synthesize variant MCAD and their similar residual MCAD activity seem to suggest that there is only one variant MCAD allele. Because the size of the variant MCAD
